Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb expanded treatment protocol of CTL019 in relapsed/refractory pediatric and young adult B-cell acute lymphoblastic leukemia
2016-001991-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tisagenlecleucel in acute lymphoblastic leukemia (ALL), sponsored by Novartis. Primary endpoint: Primary safety endpoint. Started Dec 2016; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2016-001991-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001991-31.